高级搜索

MUC1在不同免疫表型乳腺癌组织中的强阳性表达及其与预后的关系

谢轶群, 包家林, 徐 明, 裔海鹰, 黄 雷

谢轶群, 包家林, 徐 明, 裔海鹰, 黄 雷. MUC1在不同免疫表型乳腺癌组织中的强阳性表达及其与预后的关系[J]. 肿瘤防治研究, 2013, 40(08): 781-785. DOI: 10.3971/j.issn.1000-8578.2013.08.013
引用本文: 谢轶群, 包家林, 徐 明, 裔海鹰, 黄 雷. MUC1在不同免疫表型乳腺癌组织中的强阳性表达及其与预后的关系[J]. 肿瘤防治研究, 2013, 40(08): 781-785. DOI: 10.3971/j.issn.1000-8578.2013.08.013
XIE Yiqun, BAO Jialin, XU Ming, YI Haiying, Huang Lei. Strongly Positive Expression of MUC1 and Its Relationship with Prognosis in Different Immunophenotypes of Breast Cancer Tissues[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 781-785. DOI: 10.3971/j.issn.1000-8578.2013.08.013
Citation: XIE Yiqun, BAO Jialin, XU Ming, YI Haiying, Huang Lei. Strongly Positive Expression of MUC1 and Its Relationship with Prognosis in Different Immunophenotypes of Breast Cancer Tissues[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 781-785. DOI: 10.3971/j.issn.1000-8578.2013.08.013

MUC1在不同免疫表型乳腺癌组织中的强阳性表达及其与预后的关系

基金项目: 上海首批青年医师培养资助计划资助项目(沪卫人事[2012]105号);上海市黄浦区卫生事业发展奖励金资助项目(HWY-07156)
详细信息
    作者简介:

    谢轶群(1977-),女,硕士,主治医师,主要从事乳腺肿瘤的研究

    通讯作者:

    包家林,E-mail: xieyiqun@yahoo.cn

  • 中图分类号: R737.9;R730.7

Strongly Positive Expression of MUC1 and Its Relationship with Prognosis in Different Immunophenotypes of Breast Cancer Tissues

  • 摘要: 目的 探讨黏蛋白1(mucin1,MUC1)强阳性表达在不同免疫表型乳腺癌中对指导预后及个体化治疗的意义。 方法 采用免疫组织化学法检测335例乳腺癌组织中ER、PR和HER2的表达,将乳腺癌分为四个免疫表型,采用免疫组织化学法测定各免疫表型中MUC1的阳性及强阳性表达情况,并对其与不同免疫表型乳腺癌预后的关系进行统计分析。 结果 335例乳腺癌患者中MUC1强阳性表达率为46.3%,MUC1强阳性表达患者5年总生存率低于非强阳性表达者,两者之间差异存在统计学意义(P<0.05)。335例乳腺癌中ER+/PR+、HER2-型130例,ER+/PR+、HER2+型64例,ER-、PR-、HER2+型67例,ER-、PR-、HER2-型74例;MUC1强阳性表达率分别为59.2%、56.3%、32.8%和27.0%,MUC1强阳性表达与乳腺癌免疫表型相关(P<0.01)。预后分组分析表明ER+/PR+、HER2-型,ER-、PR-、HER2+型乳腺癌患者中,MUC1强阳性表达患者5年总生存率低于非强阳性表达者,差异有统计学意义(P<0.05)。 结论 MUC1强阳性表达与乳腺癌免疫表型相关,在不同免疫表型乳腺癌预后中的作用也有所不同,在ER+/PR+、HER2-型及ER-、PR-、HER2+型乳腺癌中MUC1强阳性表达提示预后较差。

     

    Abstract: Objective To explore the clinical significance of strongly positive expression (+++) of mucin1 (MUC1) for prognosis and individual treatment in different immunophenotypes of breast cancer. Methods Three hurdred and thirty-five cases of breast cancer were categorized as follows: ER+/PR+,HER2-; ER+/PR+,HER2+; ER-,PR-,HER2+ and ER-,PR-,HER2- subtype. The expression levels of ER,PR,HER2 and MUC1 were detected by mean of immunohistochemistry and the relationship between the strongly positive expression of MUC1 and prognosis of breast cancer was analyzed. Results The strongly positive rate of MUC1 in 335 cases was 46.3 %, 5-year overall survival rates(OS) of patients with strongly positive expression of MUC1 was lower (P<0.05).In 335 cases, ER+/PR+,HER2- subtype was 130, ER+/PR+,HER2+ subtype was 64, ER-,PR-,HER2+ subtype was 67 and ER-,PR-,HER2- subtype was 74. The strongly positive rate of MUC1 of four subtypes was 59.2%、56.3%、32.8% and 27.0%, respectively. The strongly positive rate of MUC1 has related to the immunophenotypes of breast cancer(P<0.01).5-year overall survival rates(OS) of patients with strongly positive expression of MUC1 was lower in ER+/PR+,HER2- and ER-,PR-,HER2+ subtype (P<0.05) by group analysis of prognosis. Conclusion The strongly positive expression of MUC1 was related to the immunophenotypes of breast cancer and played different role in prognosis of different immunophenotypes of breast cancer. The prognosis of patients with MUC1 strongly positive expression was poorer in ER+/PR+,HER2- and ER-,PR-,HER2+ subtype.

     

  • [1] Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis [J]. Clin Exp Metastasis, 2002, 19(4): 339-45.
    [2] Ren G,Yu G,Liu LW,et al.Expression and significance of MUC1 in gallbladder carcinoma[J].Zhong Liu Fang Zhi Yan Jiu,2009,36(10):844-6.[任刚,于国,刘丽威,等.MUC1蛋白在胆囊癌中的表达及其意义[J].肿瘤防治研究,2009,36(10):844-6.]
    [3] Yi HY, Xie YQ, Li Y, et al. The strongly positive expression of MUC1 in ER-positive breast cancer tissues and the relationship between MUC1 and prognosis of breast cancer[J]. Zhongguo Ai Zheng Za Zhi, 2011,21(2): 115-9.[裔海鹰,谢轶群,李圆,等.ER阳性乳腺癌中MUC1的强阳性表达及其与预后的关系[J].中国癌症杂志,2011,21(2): 115-9.]
    [4] Kondo K, Kohno N, Yokoyama A, et al. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines[J]. Cancer Res, 1998, 58(9): 2014-9.
    [5] Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784-95.
    [6] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. Arch Pathol Lab Med, 2007, 131(1): 18-43.
    [7] Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA, 2006, 295(21): 2492-502.
    [8] Schroeder JA, Thompson MC, Gardner MM, et al. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland [J]. J Biol Chem, 2001, 276(16): 13057-64.
    [9] Bensouda Y, Andr F, Boulet T, et al. Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status[J]. Bull Cancer, 2009, 96(10): 923-8.
    [10] Kufe D, Inghirami G, Abe M, et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors[J]. Hybridoma, 1984, 3(3): 223-32.
    [11] Baldus SE, Wienand JR, Werner JP, et al. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope[J]. Int J Oncol, 2005, 27(5): 1289-97.
    [12] Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy[J]. J Clin Oncol,2011, 29(29): 3885-91.
    [13] Tantivatana T, Chongthanakorn M, Rongsriyam K, et al. Treatment outcomes and prognostic factors of patients with breast cancer: a retrospective review[J]. J Med Assoc Thai,2009, 92(8): 1084-93.
    [14] Chen XS, Ma CD, Wu JY, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer[J]. Tumori,2010, 96(1): 103-10.
    [15] Wei X, Xu H, Kufe D.MUC1 oncoprotein stabilizes and activates estrogen receptor alpha[J]. Mol Cell, 2006, 21(2): 295-305.
    [16] Khodarev N, Ahmad R, Rajabi H, et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer [J]. Oncogene, 2010, 29(6): 920-9.
    [17] Khodarev NN, Pitroda SP, Beckett MA, et al.MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment [J]. Proc Natl Acad Sci U S A, 2009, 106(14): 5837-41.
    [18] Fessler SP, Wotkowicz MT, Mahanta SK, et al. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells[J]. Breast Cancer Res Treat,2009, 118(1): 113-24.
    [19] Cheng JP, Yan Y, Wang XY, et al. MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer[J]. Chin J Cancer,2011, 30(1): 54-61.
计量
  • 文章访问数:  2110
  • HTML全文浏览量:  14
  • PDF下载量:  404
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-08-07
  • 修回日期:  2013-01-30
  • 刊出日期:  2013-08-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭